报价延迟最少15分钟:2024/12/25 01:19 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.88 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.15/0.32
|
|
企业价值
5.17B
|
| 资产负债 |
|
每股账面净值
0.75
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2024/12/25 01:19 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. |